Emi Minejima1,2, Nikki Mai1, Nancy Bui1, Melissa Mert3, Wendy J Mack4, Rosemary C She5, Paul Nieberg6, Brad Spellberg2,7, Annie Wong-Beringer1,8. 1. Department of Clinical Pharmacy, University of Southern California (USC) School of Pharmacy, Los Angeles. 2. Los Angeles County and USC Medical Center, Los Angeles. 3. Departments of Preventive Medicine and Clinical and Translational Science Institute, Los Angeles. 4. Departments of Preventive Medicine of Keck School of Medicine, Los Angeles. 5. Departments of Pathology, Keck School of Medicine at USC, Los Angeles. 6. Department of Medicine-Infectious Diseases, Huntington Hospital, Pasadena, California. 7. Department of Medicine, Keck School of Medicine at USC, Los Angeles. 8. Department of Pharmacy, Huntington Hospital, Pasadena, California.
Abstract
BACKGROUND: Persistent Staphylococcus aureus bacteremia (SAB) is defined based on varying duration in literature. The primary objective was to determine the risk of poor outcomes in relation to bacteremia duration. METHODS: Multicenter, prospective, observational study of adult hospitalized patients with SAB. Medical records were reviewed for pertinent data. Patients were grouped by bacteremia duration: short (1-2 days), intermediate (3-6 days), and prolonged (≥7 days) and compared for risk factors and outcomes. RESULTS: Of 884 patients, 63% had short, 28% intermediate, and 9% prolonged bacteremia. Overall mean age was 57 years, and 70% were male. The prolonged group had the highest proportion of methicillin-resistant SAB (P < .0001). Choice of antibiotic therapy did not significantly affect bacteremia duration; however, time to source-control procedure was delayed in the prolonged and intermediate groups compared with the short group (3.5 vs 3 vs 1 day, P < .0001). Metastatic complications, length of stay, and 30-day mortality were progressively worse as bacteremia duration increased (P < .0001). Every continued day of bacteremia was associated with a relative risk of death of 1.16 (95% confidence interval, 1.10-1.22; P < .0001), with a significant increase in risk starting at 3 days as determined by receiver operating characteristic analysis. CONCLUSIONS: Optimal management of SAB should target bacterial clearance as soon as possible to minimize incremental risk of mortality with each day of positive blood culture. Delay in source control but not type of antistaphylococcal therapy was significantly associated with prolonged bacteremia and worse outcomes.
BACKGROUND: Persistent Staphylococcus aureus bacteremia (SAB) is defined based on varying duration in literature. The primary objective was to determine the risk of poor outcomes in relation to bacteremia duration. METHODS: Multicenter, prospective, observational study of adult hospitalized patients with SAB. Medical records were reviewed for pertinent data. Patients were grouped by bacteremia duration: short (1-2 days), intermediate (3-6 days), and prolonged (≥7 days) and compared for risk factors and outcomes. RESULTS: Of 884 patients, 63% had short, 28% intermediate, and 9% prolonged bacteremia. Overall mean age was 57 years, and 70% were male. The prolonged group had the highest proportion of methicillin-resistant SAB (P < .0001). Choice of antibiotic therapy did not significantly affect bacteremia duration; however, time to source-control procedure was delayed in the prolonged and intermediate groups compared with the short group (3.5 vs 3 vs 1 day, P < .0001). Metastatic complications, length of stay, and 30-day mortality were progressively worse as bacteremia duration increased (P < .0001). Every continued day of bacteremia was associated with a relative risk of death of 1.16 (95% confidence interval, 1.10-1.22; P < .0001), with a significant increase in risk starting at 3 days as determined by receiver operating characteristic analysis. CONCLUSIONS: Optimal management of SAB should target bacterial clearance as soon as possible to minimize incremental risk of mortality with each day of positive blood culture. Delay in source control but not type of antistaphylococcal therapy was significantly associated with prolonged bacteremia and worse outcomes.
Authors: Maggie J Box; Eva L Sullivan; Kristine N Ortwine; Mark A Parmenter; Michael M Quigley; Louise M Aguilar-Higgins; Cynthia L MacIntosh; Kristina F Goerke; Rachel A Lim Journal: Pharmacotherapy Date: 2015-03 Impact factor: 4.705
Authors: Sebastian J van Hal; Slade O Jensen; Vikram L Vaska; Björn A Espedido; David L Paterson; Iain B Gosbell Journal: Clin Microbiol Rev Date: 2012-04 Impact factor: 26.132
Authors: Warren E Rose; Jens C Eickhoff; Sanjay K Shukla; Madhulatha Pantrangi; Suzan Rooijakkers; Sara E Cosgrove; Victor Nizet; George Sakoulas Journal: J Infect Dis Date: 2012-09-10 Impact factor: 5.226
Authors: Thea Chua; Carol L Moore; Mary B Perri; Susan M Donabedian; William Masch; Dora Vager; Susan L Davis; Kaitlin Lulek; Benjamin Zimnicki; Marcus J Zervos Journal: J Clin Microbiol Date: 2008-05-28 Impact factor: 5.948
Authors: Joe Pardo; Kenneth P Klinker; Samuel J Borgert; Brittany M Butler; Patricia G Giglio; Kenneth H Rand Journal: Diagn Microbiol Infect Dis Date: 2015-11-11 Impact factor: 2.803